Supernus Pharmaceuticals Shares Outstanding 2011-2024 | SUPN

Supernus Pharmaceuticals shares outstanding from 2011 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Supernus Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2023 56
2022 62
2021 54
2020 54
2019 54
2018 54
2017 53
2016 52
2015 51
2014 42
2013 32
2012 17
2011 2
2010 2
Supernus Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2024-06-30 56
2024-03-31 56
2023-12-31 56
2023-09-30 55
2023-06-30 55
2023-03-31 62
2022-12-31 62
2022-09-30 55
2022-06-30 61
2022-03-31 61
2021-12-31 54
2021-09-30 54
2021-06-30 55
2021-03-31 54
2020-12-31 54
2020-09-30 54
2020-06-30 54
2020-03-31 54
2019-12-31 54
2019-09-30 54
2019-06-30 54
2019-03-31 54
2018-12-31 54
2018-09-30 54
2018-06-30 54
2018-03-31 54
2017-12-31 53
2017-09-30 54
2017-06-30 53
2017-03-31 53
2016-12-31 52
2016-09-30 52
2016-06-30 52
2016-03-31 51
2015-12-31 51
2015-09-30 52
2015-06-30 52
2015-03-31 45
2014-12-31 42
2014-09-30 43
2014-06-30 42
2014-03-31 41
2013-12-31 32
2013-09-30 31
2013-06-30 31
2013-03-31 31
2012-12-31 17
2012-09-30 24
2012-06-30 17
2012-03-31 2
2011-12-31 2
2011-09-30 2
2011-06-30 2
2011-03-31 2
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.872B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00